In the shPrPc HCT116 xenograft models, TRAIL treatment led to a significant decrease in tumor volume associated with lower PrPc expression, even though the expression of HIF-1α increased in the xenograft tumor mass, indicating that silencing of PrPc protein is an efficient strategy to inhibit colon cancer development (Figure 7). This evidence concerns the gene HIF1A and neoplasm.